Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program

Saturday, October 11, 2008 General News J E 4
EMERYVILLE, Calif., Oct. 10 NeurobiologicalTechnologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will hold aconference call on Monday, October 13, to provide an update on theViprinex(TM) (ancrod) Phase 3 Trial Program for acute ischemic stroke.Hosting the call will be Paul E. Freiman, president and chief executiveofficer and Warren W. Wasiewski, chief medical officer.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceuticalcompany focused on developing novel, first-in-class agents for central nervoussystem conditions and other serious unmet medical needs. The Company's mostadvanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinicaltesting as a novel investigational drug for the treatment of acute ischemicstroke. Viprinex has multiple mechanisms of action and is specificallydesigned to extend the time period that patients can be treated after theonset of a stroke. Acute ischemic stroke is one of the most prevalent,debilitating and costly diseases in the world for which there are fewacceptable treatment options. NTI also has early-stage development programsfor Alzheimer's and Huntington's diseases and rights to receive payments on anapproved drug for Alzheimer's disease and an investigational drug in Phase 3trials for brain swelling.-- Date: Monday, October 13, 2008 -- Time: 1:00 p.m. (ET), 12:00 p.m. (CT), 10:00 a.m. (PT) -- Dial-in number: 877-440-5803 U.S. & Canada / 719-325-4942 International Telephonic Replay: A playback of the conference call will be available from 1:00 p.m. (ET) on October 13, 2008 to midnight (ET) on October 20, 2008. Replay number: 888-203-1112 U.S. / 719-457-0820 International Pass code: 9164451

SOURCE Neurobiological Technologies, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Hologic, Inc. To Release Fourth Quarter and Fiscal...
Virginia Rehabilitation Center for the Blind and V...